CSIMarket
 
Teva Pharmaceutical Industries Limited  (TEVA)
Other Ticker:  
 
 
Price: $13.4300 $-0.07 -0.519%
Day's High: $13.65 Week Perf: 0.6 %
Day's Low: $ 13.35 30 Day Perf: 1.97 %
Volume (M): 6,235 52 Wk High: $ 13.93
Volume (M$): $ 83,740 52 Wk Avg: $9.64
Open: $13.38 52 Wk Low: $7.09



 Market Capitalization (Millions $) 15,015
 Shares Outstanding (Millions) 1,118
 Employees 40,000
 Revenues (TTM) (Millions $) 15,845
 Net Income (TTM) (Millions $) -615
 Cash Flow (TTM) (Millions $) 393
 Capital Exp. (TTM) (Millions $) 546

Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that specializes in the development, manufacture, and distribution of generic drugs, specialty medicines, and active pharmaceutical ingredients. The company was founded in Jerusalem, Israel in 1901, and has since grown to become one of the largest pharmaceutical companies in the world, with operations in more than 60 countries.

Teva's portfolio of products includes a wide range of generic and branded drugs, including medications for chronic and acute conditions, injectable drugs, biosimilars, and over-the-counter medicines. The company's size and scale allow it to offer affordable medications for a diverse range of conditions, helping to ensure that patients have access to the treatments they need.

In addition to its core business of manufacturing and distributing pharmaceuticals, Teva is also involved in drug development and research. The company has an R&D team dedicated to developing new drugs and technologies, with a particular focus on therapeutic areas such as central nervous system disorders, respiratory diseases, and oncology.

Teva is committed to environmental sustainability and ethical business practices. The company has implemented various programs to reduce its environmental impact, such as reducing water and energy use, and minimizing waste. Teva is also dedicated to promoting patient safety and ethical conduct, and has established strong compliance and ethics programs to ensure that all employees act with integrity and adhere to the highest ethical standards.

Teva employs more than 42,000 people worldwide and has a revenue of over $16 billion. The company is headquartered in Petah Tikva, Israel and operates manufacturing facilities all over the world, including in the United States, Europe, and Asia. Teva has an extensive global distribution network, allowing it to reach patients in nearly every corner of the world.


   Company Address: 124 Dvora HaNevi?a St. Tel Aviv 6944020
   Company Phone Number: 914-8213   Stock Exchange / Ticker: NYSE TEVA
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMRX        2.23% 
AMGN   -2.04%    
• View Complete Report
   



Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited Reports Impressive Financial Results, Establishes Itself as a Leader in the Pharmaceutical Industry



In a surprising twist of events, Teva Pharmaceutical Industries Limited has recently reported impressive financial results that have captured the attention of the stock market. The company displays a significant improvement across key indicators, demonstrating its resilience and adaptability within a challenging market environment. Teva's positive bottom-line and extraordinary growth in earnings per share (EPS) have positioned the company as a frontrunner in the pharmaceutical industry.
Robust Financial Performance:
Teva's financial interval ending on December 31, 2023, witnessed a remarkable transformation in its earnings. The company's bottom-line surged to $0.38 per share, representing a stark improvement from $-1.10 per share the previous year. This outstanding growth in EPS amounted to an impressive 446.22% increase from $0.07 per share in the preceding quarter.

Teva Pharmaceutical Industries Limited

Steady Growth and Strategic Moves Propel Teva Pharmaceutical Industries Limited to New Heights in Latest Financial Quarter

Teva Pharmaceutical Industries Limited: A Bearish Outlook
Teva Pharmaceutical Industries Limited, a major player in the pharmaceutical preparations industry, recently released its financial results for the period of July to September 30, 2023. While the company reported an increase in revenue compared to the same period last year, there are several concerning factors that point towards a bearish outlook for the company.
Firstly, the increase in revenue of 7.093% to $3.85 billion may seem positive on the surface. However, when compared to the previous quarter's revenue of $3.88 billion, it is evident that there has been a decline of -0.722%. This indicates a potential trend of decreasing revenue, which is a worrying sign for investors.

Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Dramatically Shakes Off Massive Shortfall, Surging Back with an Impressive Revenue Uptick in Q2 2023

Teva Pharmaceutical Industries Limited, a global pharmaceutical company, recently released its financial results for the second quarter of 2023. The company reported a significant increase in shortfall per share compared to the same quarter last year and the preceding quarter.
In the financial second quarter of 2023, TEVA recorded a shortfall per share of $-0.77, which is a considerable increase from $-0.21 per share in the corresponding period a year ago. Additionally, there was a sequential increase in shortfall from $-0.18 per share from the previous quarter. These figures indicate a decline in profitability for the company during this quarter.

Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited Takes Steps Towards Financial Recovery in First Quarter of 2023, Aiming to Overcome Revenue Shortfall

Teva Pharmaceutical Industries Limited has reported a drop in its revenue per employee over the past year, falling from $457,925 to $373,125 on a trailing twelve month basis. According to industry data, 160 other companies in the healthcare sector have achieved higher revenue per employee than Teva.
The company, which employs around 40,000 people, has seen its overall ranking deteriorate from 0 to 1628 compared to the fourth quarter of 2022. It is clear that Teva is facing stiff competition from its peers in the industry.






 

Teva Pharmaceutical Industries Limited's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Teva Pharmaceutical Industries Limited does not provide revenue guidance.

Earnings Outlook
Teva Pharmaceutical Industries Limited does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com